3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
3
Status
Not yet recruiting
2
Recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
11
Thoracic
8
Gastrointestinal
7
Lymphoid
5
Tumor-Agnostic
4
Other hematologic neoplasm
4
Plasma cell
3
Genitourinary
3
Other
1
Dermatologic
1
CNS
1
Conditions
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Prostatic Neoplasms
1
Peripheral Nervous System Diseases
1
Motor Activity
1
Fatigue
1
Interventions
Magnetic Resonance Spectroscopy
101
Specimen Handling
83
pembrolizumab
76
enzalutamide
63
Nivolumab
59
Gemcitabine
56
Docetaxel
50
apalutamide
42
Radiosurgery
42
Abiraterone Acetate
40
Prednisone
39
Androgen Antagonists
39
Cisplatin
37
Biopsy
37
darolutamide
36
cabozantinib
32
Radiotherapy
32
Pluvicto
28
Carboplatin
28
abiraterone
27
Ipilimumab
25
enfortumab vedotin
24
durvalumab
24
Radiation
23
atezolizumab
22
X-Rays
21
Leuprolide
20
Standard of Care
19
olaparib
18
avelumab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Exercise
×
Genitourinary
×
90 days
×
Clear all
NCT07548476
2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA
Not yet recruiting
50 enrolled
NCT07518888
2026-04-09
ESCAPE
University of Miami
Phase NA
Not yet recruiting
49 enrolled
NCT05588700
2026-03-31
STARTER
Centre Leon Berard
Phase NA
Recruiting
236 enrolled